Patents by Inventor Russell B. Lingham

Russell B. Lingham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6541515
    Abstract: Compounds useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines are described. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. The culture Cytospora sp. MF 6608 (ATCC PTA-1691) is also disclosed, as well as processes for making a compound of the present invention employing the culture.
    Type: Grant
    Filed: August 9, 2001
    Date of Patent: April 1, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Sheo Bux Singh, Hiranthi Jayasuriya, Ziqiang Guan, Keith C. Silverman, Russell B. Lingham, Anne W. Dombrowski, Daria J. Hazuda, Jon D. Polishook
  • Patent number: 6403347
    Abstract: Natural products such as certain chaetochromins are described. These compounds are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: October 25, 1999
    Date of Patent: June 11, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Gerald F. Bills, Russell B. Lingham, Ali Shafiee, Keith C. Silverman, Sheo Bux Singh, Deborah L. Zink, Fernando Pelaez, Ana M. Teran
  • Publication number: 20020045658
    Abstract: Compounds useful in the inhibition of HIV integrase, the prevention or treatment of infection by HV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines are described. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. The culture Cytospora sp. MF 6608 (ATCC PTA-1691) is also disclosed, as well as processes for making a compound of the present invention employing the culture.
    Type: Application
    Filed: August 9, 2001
    Publication date: April 18, 2002
    Inventors: Sheo Bux Singh, Hiranthi Jayasuriya, Ziqiang Guan, Keith C. Silverman, Russell B. Lingham, Anne W. Dombrowski, Daria J. Hazuda, Jon D. Polishook
  • Patent number: 6124327
    Abstract: Natural products such as certain dimerized hydroxyphenylundecanes are described. These compounds are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: July 27, 1998
    Date of Patent: September 26, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Keith C. Silverman, Russell B. Lingham, Sheo Bux Singh, Deborah L. Zink, Ana Teran
  • Patent number: 6110716
    Abstract: Natural products such as certain chaetochromins are described. These compounds are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: February 4, 1998
    Date of Patent: August 29, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Russell B. Lingham, Ali Shafiee, Keith C. Silverman, Ana M. Teran, Sheo Bux Singh, Deborah L. Zink
  • Patent number: 5858738
    Abstract: Natural products such as certain ermophilane sesquiterpenoids and derivatives thereof are described. These compounds are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described. The fungal culture MF6254, Xylaria sp. (ATCC 74397) is also described and disclosed.
    Type: Grant
    Filed: November 4, 1997
    Date of Patent: January 12, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Russell B. Lingham, Jon David Polishook, Ali Shafiee, Keith C. Silverman, Sheo Bux Singh, Deborah L. Zink
  • Patent number: 5789438
    Abstract: The present invention is directed to steroidal or terpenoidal compounds which inhibit farnesyl-protein transferase (FPTase). The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and treatment of cancer.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: August 4, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Sheo B. Singh, Russell B. Lingham, Keith C. Silverman, Deborah L. Zink, Isabel Martin, Fernando Pelaez, Manuel Sanchez
  • Patent number: 5703067
    Abstract: The present invention is directed to steroidal or terpenoidal compounds which inhibit farnesyl-protein transferase (FPTase). The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and treatment of cancer.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: December 30, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Hiranthi Jayasuriya, Russell B. Lingham, Fernando Pelaez, Manuel Sanchez, Keith C. Silverman, Sheo Bux Singh, Deborah L. Zink
  • Patent number: 5663193
    Abstract: The present invention is directed to non-peptide compounds which inhibit farnesyl-protein transferase (FPTase) and the farnesylation of the oncogene protein Ras. The invention also relates to the process for the preparation of a compound of this invention by cultivating a culture of Phoma sp. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: July 17, 1996
    Date of Patent: September 2, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Carmen Cascales, Russell B. Lingham, Fernando Pelaez, Jon D. Polishook, Keith C. Silverman, Sheo B. Singh, Deborah L. Zink
  • Patent number: 5627057
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FPTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras. Furthermore, Actinoplanes sp. ATCC 55532 and Streptomces sp. ATCC 55550 are microorganisms which are capable of producing the disclosed compounds which are classified as carboxylic acid esters. In addition a method for preparing the compounds is disclosed which includes cultivating strain ATCC 55532 or strain ATCC 55550. The strains are independently capable of producing the carboxylic acid ester compounds.
    Type: Grant
    Filed: March 6, 1996
    Date of Patent: May 6, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Sheo B. Singh, George M. Garrity, Olga Genillourd, Russell B. Lingham, Isabel Martin, Mary Nallin-Omstead, Keith C. Silverman, Deborah L. Zink
  • Patent number: 5510371
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FPTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: June 6, 1994
    Date of Patent: April 23, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Sheo B. Singh, George M. Garrity, Olga Genillourd, Russell B. Lingham, Isabel Martin, Mary N. Omstead, Keith C. Silverman, Deborah L. Zink
  • Patent number: 5436263
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FPTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: March 22, 1994
    Date of Patent: July 25, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Sheo B. Singh, Barry A. Katz, Russell B. Lingham, Isabel Martin, Keith C. Silverman
  • Patent number: 5420157
    Abstract: This invention relates to pharmaceutical compounds of structural formulae (I) and (II): ##STR1## and compositions and methods of treatment utilizing these compounds to inhibit farnesyl protein transferase and farnesylation of the oncogene protein Ras.
    Type: Grant
    Filed: December 16, 1991
    Date of Patent: May 30, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Sheo B. Singh, Gerald F. Bills, Russell B. Lingham, Keith C. Silverman, Deborah L. Zink
  • Patent number: 5420334
    Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FPTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting famesyl-protein transferase and the famesylation of the oncogene protein Ras.
    Type: Grant
    Filed: April 4, 1994
    Date of Patent: May 30, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Sheo B. Singh, Gerald F. Bills, Russell B. Lingham, Isabel Martin, Keith C. Silverman, Jack L. Smith
  • Patent number: 5283256
    Abstract: This invention relates to compounds of structural formula (I): ##STR1## which are squalene synthase inhibitors and thus useful as cholesterol lowering agents and antifungal agents. These compounds are also inhibitors of farnesyl protein transferase and farnesylation of the oncogene protein Ras and thus useful in treating cancer. This invention also relates to a process for obtaining compounds of structural formula (I).
    Type: Grant
    Filed: July 22, 1992
    Date of Patent: February 1, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Claude Dufresne, Josep Guarro, Leeyuan Huang, Yu L. Kong, Russell B. Lingham, Maria S. Meinz, Keith C. Silverman, Sheo B. Singh
  • Patent number: 5250563
    Abstract: Novel cytochalasins are the biotransformed products after incubation with a substrate in a culture of the microorganism Kibdelosporangium sp. (Merck Culture Collection MA 6559), ATCC No. 53771. The compounds of the present invention inhibit HIV protease and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: September 25, 1992
    Date of Patent: October 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Shieh-Shung T. Chen, George A. Doss, Russell B. Lingham
  • Patent number: 5192668
    Abstract: A dipeptide isostere is the biotransformed product after incubation with a culture of Streptomyces. It inhibits HIV protease, and is useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: March 9, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Laszlo R. Treiber, Lawrence F. Colwell, Jr., Byron H. Arison, Georgette Dezeny, Russell B. Lingham, Wayne J. Thompson, Suresh K. Balani
  • Patent number: 5187074
    Abstract: A novel dipeptide isostere is the biotransformed product after incubation with a culture of Streptomyces. It inhibits HIV protease, and is useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: February 20, 1992
    Date of Patent: February 16, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Laszlo R. Treiber, Russell B. Lingham, Byron H. Arison, Lawrence F. Colwell, Jr., Georgette Dezeny, Nancy E. Kohl
  • Patent number: 5183826
    Abstract: An antiviral agent produced by Hypoxylon fragiforme and having the structure: ##STR1## is described. The product has high activity as an HIV protease enzyme inhibitor and is useful in the treatment of diseases in which control of HIV protease activity is desirable.
    Type: Grant
    Filed: September 25, 1990
    Date of Patent: February 2, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Gerald F. Bills, Otto D. Hensens, Lawrence Koupal, Russell B. Lingham, John G. Ondeyka, Deborah L. Zink